Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innate Pharma's Expanded IO AstraZeneca Deal Jump-Starts US Ambitions

Executive Summary

France's Innate Pharma gets a boost to its plans to become a fully integrated biotech by forging a long-term immuno-oncology development partnership with AstraZeneca, and the setting up of a commercialization team in the US.

 

Advertisement

Related Content

AstraZeneca Q3 Sales Rise 'Is Milestone', CEO Soriot 'Not Leaving'
Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna
Innate's Lirilumab In Limbo After Phase II Combo Failure
Celgene pays $450m for AZ's MEDI4736 in blood cancers; AZ signs $250m+ Innate deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel